Prognosis of amnestic mild cognitive impairment: clinical and immunological correlations

Ponomareva E.V.; Krynskiy S.A.; Gavrilova S.I.

doi:https://doi.org/10.17116/jnevro202112110216

Ponomareva E.V.

Mental Health Research Center

Krynskiy S.A.

National Research Center «Kurchatov Institute»

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Prognosis of amnestic mild cognitive impairment: clinical and immunological correlations

Authors:

Ponomareva E.V., Krynskiy S.A., Gavrilova S.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10‑2): 16‑22

DOI: 10.17116/jnevro202112110216

Read: 2724 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ponomareva EV, Krynskiy SA, Gavrilova SI. Prognosis of amnestic mild cognitive impairment: clinical and immunological correlations. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10‑2):16‑22. (In Russ.)
https://doi.org/10.17116/jnevro202112110216

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

Abstract:

OBJECTIVE

To determine the long-term (three-year) prognosis of the cognitive deficits progression in elderly people with amnestic mild cognitive impairment (aMCI) based on the analysis of the initial clinical and immunological parameters.

MATERIAL AND METHODS

This study is based on a clinical and follow-up study of 252 outpatients with aMCI, who were observed in the Federal State Budgetary Scientific Institution «Mental Health Research Center» from 2018 to 2020. The psychometric assessment complex included the following scales and tests: MMSE, MoCA, The 10 words test, BNT, David Wechsler’s Scale, subtest 6, CDT, Memory test of 5 geometric shapes, BVRT Test, DRS — Mattis Dementia Rating Scale: Verbal fluency, DRS — Mattis Dementia Rating Scale, The Munsterberg Test. As part of the study, the level of cytokines (TNF-a, IL-1, IL-6, IL-8, IL-10) in the blood serum was determined in all patients by enzyme immunoassay (ELISA), using diagnostic kits manufactured by Cytokine LLC.

RESULTS

In patients with a progression of aMCI syndrome, an increase in proinflammatory cytokines IL-1, IL-6, IL-8, TNF-α is initially detected, which may reflect the level of systemic inflammation or functional insufficiency of anti-inflammatory mechanisms. In turn, the group with a subsequent improvement in cognitive functioning, on the contrary, is distinguished by an initially increased level of the anti-inflammatory interleukin system (IL-10).

CONCLUSION

We provide new data on the presence of systemic inflammation and immune disturbances and their association with clinical course of disease in the majority of elderly patients with aMCI.

CONCLUSION

Signs of a chronic low-level systemic inflammatory response in patients with aMCI is the unfavorable prognosis criterion: in such patients, cognitive deficit significantly progresses or dementia due to Alzheimer disease develops within three years.

Keywords:

amnestic Mild Cognitive Impairment

immunological examination

Authors:

Ponomareva E.V.

Mental Health Research Center

Krynskiy S.A.

National Research Center «Kurchatov Institute»

Gavrilova S.I.

Mental Health Research Centre

SPIN RSCI: 6094-4303
Scopus AuthorID: 7004829216
ResearcherID: B-4548-2016
ORCID: 0000-0001-6683-0240

Received:

09.08.2021

Accepted:

16.08.2021

Close metadata

References:

Albert MS, Dekosky ST, Dickson D, Dickson D, Dubois B, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s Association workgroup on diagnostic guidelines for Alzheimer’s disease. Alzheimers & Dementia. 2011;7(3):270-279. https://doi.org/10.1016/j.jalz.2011.03.008
Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308. https://doi.org/10.1001/archneur.56.3.303
Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61(1):59-66. https://doi.org/10.1001/archneur.61.1.59
Petersen RC. Mild Cognitive Impairment. Continuum (Minneap Minn). Review. 2016;22(2):404-4018. https://doi.org/10.1212/CON.0000000000000313
Busse A1, Hensel A, Gühne U, Angermeyer MC, Riedel-Heller SG. Mild cognitive impairment: long-term course of four clinical subtypes. Neurology. 2006;67(12):2176-2185. https://doi.org/10.1212/01.wnl.0000249117.23318.e1
Manly JJ1, Tang MX, Schupf N, Stern Y, Vonsattel JP, Mayeux R. Frequency and course of mild cognitive impairment in a multiethnic community. Ann Neurol. 2008;63(4):494-506. https://doi.org/10.1002/ana.21326
Michaud TL, Su D., Siahpush M., Murman DL. The Risk of Incident Mild Cognitive Impairment and Progression to Dementia Considering Mild Cognitive Impairment Subtypes. Dement Geriatr Cogn Dis Extra. 2017;7(1):15-29. https://doi.org/10.1159/000452486
Klyushnik TP, Androsova LV, Mikhailova NM, Sokolov AV, Kostevich VA, Zakharova ET, Vasil’ev VB. Potential markers of Alzheimer’s disease associated with inflammation. Psychiatry. 2014;1:28-34. (In Russ.).
Androsova LV, Klyushnik TP, Zozulya SA, Mikhaylova NM. Leukocyte elastase and interleukins in Alzheimer,s disease. Neurodegenerative diseases. 2013;11(1):1173.
Schram MT, Euser SM, de Craen AJ, Witteman JC, Frölich M, Hofman A, et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc. 2007;55(5):708-716. https://doi.org/10.1111/j.1532-5415.2007.01159.x
Malashenkova IK, Krynskiy SA, Hailov NA, Kazanova GV, et al. The role of cytokines in memory consolidation. Biology Bulletin Reviews. 2016;6(2):126-140. https://doi.org/10.1134/s2079086416020055
Simonov AN, Klyushnik TP, Androsova LV, Mikhailova NM. Quantitative assessment of the association of inflammatory markers with Alzheimer’s disease. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2018;118(5):58-63. (In Russ.). https://doi.org/10.17116/jnevro20181185158
Ward A, Tardiff S, Dye C, Arrighi HM. Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia: a systematic review of the literature. Dement Geriatr Cogn Dis Extra. 2013;3(1):320-332. https://doi.org/10.1159/000354370
Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic — vs community-based cohorts. Arch Neurol. 2009;66:1151-1157. https://doi.org/10.1001/archneurol.2009.106
Cai Z1, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int J Neurosci. 2014;124(5):307-321. https://doi.org/10.3109/00207454.2013.833510
Kuhla A, Ludwig SC, Kuhla B et al. Advanced glycation end products are mitogenic signals and trigger cell cycle reentry of neurons in Alzheimer’s disease brain. Neurobiol Aging. 2015;36(2):753-761. https://doi.org/10.1016/j.neurobiolaging.2014.09.025
Kavacheva NV, Salmina AB, Komleva YuK, Malinovskaya NA, Morgun AV, Pozhrenkova EA, Zamay GS, Yauzina NA, Petrova MM. The permeability of the blood-brain barrier in normal conditions, in cases of impaired brain development and neurodegeneration. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2013;113(4):80-85. (In Russ.).
Skaper SD, Facci L, Zusso M, Giusti P. An Inflammation-Centric View of Neurological Disease: Beyond the Neuron. Front Cell Neurosci. 2018;12:72. https://doi.org/10.3389/fncel.2018.00072
Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with the sphingomyelin pathway in the development of Alzheimer’s disease. Biochem Soc Trans. 2004;32(1):144-146. https://doi.org/10.1042/bst0320144
Menachem-Zidon BO, Avital A, Ben-Menahem Y et al. Astrocytes support hippocampal-dependent memory and long-term potentiation via interleu- kin-1 signaling. Brain Behav Immun. 2011;25(5):1008-1016. https://doi.org/10.1016/j.bbi.2010.11.007
Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines re- leased from microglia in Alzheimer’s disease. Ann Transl Med. 2015;3(10):136. https://doi.org/10.3978/j.issn.2305-5839.2015.03.49
Belkhelfa M, Rafa H, Medjeber O et al. IFN-γ and TNF-α are involved during Alzheimer disease progression and correlate with nitric oxide pro- duction: a study in Algerian patients. J Interferon Cytokine Res. 2014;34(11):839-847. https://doi.org/10.1089/jir.2013.0085
Trollor JN, Smith E, Baune BT, Kochan NA, Campbell L, Samaras K, Crawford J, Brodaty H, Sachdev P. Systemic inflammation is associated with MCI and its subtypes: the Sydney Memory and Aging Study. Dement Geriatr Cogn Disord. 2010;30(6):569-578. https://doi.org/10.1159/000322092
King E, O’Brien JT, Donaghy P, Morris C, Barnett N, Olsen K, Martin-Ruiz C, Taylor JP, Thomas AJ. Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias. J Neurol Neurosurg Psychiatry. 2018;89(4):339-345. https://doi.org/10.1136/jnnp-2017-317134
Fedorova YaB. Soft cognitive decline syndrome: psychopathological structure and paraclinical (psychometric, neurointrascopic, and molecular-genetic) characteristics. Journal of Psychiatry. 2006;4:15-22. (In Russ.).
Gavrilova SI, Fedorova YaB, Roshchina IF, Korovaytseva GI. Prognosis of mild cognitive impairment according to a two-year clinical and catamnestic study. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2007;1:4-10. (In Russ.).